Clinical Report: New Perspectives on Triple-Negative Breast Cancer and Matrix Stiffness

Overview

This study investigates the impact of matrix stiffness on the biological behaviors and prognosis of triple-negative breast cancer (TNBC). It establishes a prognostic model based on matrix stiffness-related genes, demonstrating its potential to predict treatment response and patient survival across multiple cohorts.

Background

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks targeted therapy options, resulting in poor patient outcomes. The tumor microenvironment, particularly matrix stiffness, plays a crucial role in tumor progression and treatment resistance. Understanding the relationship between matrix stiffness and TNBC can lead to improved prognostic assessments and therapeutic strategies.

Data Highlights

Key Findings

• Malignant epithelial cells with high MS scores exhibit unique functional states.
• The MS-based prognostic model predicts survival risk effectively across cohorts.
• MS score is an independent prognostic factor confirmed by multivariate analysis.
• The nomogram incorporating clinical parameters shows good calibration and clinical benefit.
• A high MS score is linked to resistance to immunotherapy and reduced chemotherapy sensitivity.

Clinical Implications

The findings suggest that assessing matrix stiffness could enhance prognostic evaluations for TNBC patients. Incorporating MS scores into clinical practice may help tailor treatment strategies and improve patient outcomes by identifying those at higher risk of treatment resistance.

Conclusion

This study underscores the significance of matrix stiffness in TNBC prognosis and treatment response, providing a foundation for future research and clinical applications in precision medicine.

Related Resources & Content

1. The ASCO Post, 2024 -- Overall Survival Analysis Confirms Pembrolizumab Regimen as Standard of Care for Triple-Negative Breast Cancer
2. The ASCO Post, 2012 -- Next-generation Sequencing in Metastatic Triple-negative Breast Cancer Yields Rewards
3. The ASCO Post, 2017 -- Genomic Characteristics and Immune Infiltration in Triple-Negative Breast Cancer
4. asco ai in oncology, 2026 -- Transcriptomic Classifier for Predicting Neoadjuvant Immunotherapy Response in Triple-Negative Breast Cancer
5. The ASCO Post, 2014 -- Extracellular Matrix Stiffness Promotes Malignant Progression Via PTEN-Reducing Effect of Micro-RNA
6. Overall Survival Analysis Confirms Pembrolizumab Regimen as Standard of Care for Triple-Negative Breast Cancer - The ASCO Post
7. KEYNOTE-355 Final Analysis Reveals Survival Benefit With Pembrolizumab in Triple-Negative Breast Cancer - The ASCO Post
8. Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications | Nature Communications